United States Biotechnology & Medical Research

CEL-SCI Corp (CVM)

Track

In the last 90 days, CEL-SCI Corp has seen insider buying totaling $479,000, with the CEO being the sole executive involved. This activity represents 0.05% of the company's float. The stock has experienced a significant price decline of 61.4% over the past 90 days, trading near its 52-week low.
Stock chart
Ticker: CVM Exchange: ASE
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
KERSTEN GEERT R
Chief Executive Officer
1 purchase — total 100,000 USD
Buy 14 May 2026
Value US$3,842,494.73 | Price 246.80 | Shares 75,825
Buy 13 May 2026
Value US$4,350,766.44 | Price 494.55 | Shares 99,793
Buy 22 Jan 2026
Value US$200,000.98 | Price 5.26 | Shares 38,023
Buy 4 Dec 2025
Value US$49,998.44 | Price 5.96 | Shares 8,389
Buy 25 Jul 2025
Value US$19,995.15 | Price 6.85 | Shares 2,919
Buy 25 Jul 2025
Value US$199,999.45 | Price 6.85 | Shares 29,197
Buy 8 May 2024
Value US$27,800.00 | Price 1.39 | Shares 20,000
Buy 8 May 2024
Value US$27,800.00 | Price 1.39 | Shares 20,000
Buy 8 May 2024
Value US$11,120.00 | Price 1.39 | Shares 8,000
Buy 8 May 2024
Value US$41,700.00 | Price 1.39 | Shares 30,000
Sale 19 Oct 2021
Value US$168,750.00 | Price 11.25 | Shares 15,000
Buy 6 Jul 2021
Value US$10,000.00 | Price 8.00 | Shares 1,250
Buy 28 Jun 2021
Value US$37,971.00 | Price 12.66 | Shares 3,000
Sale 22 Apr 2021
Value US$243,793.00 | Price 24.38 | Shares 10,000
Buy 11 Dec 2020
Value US$1,424.00 | Price 14.24 | Shares 100
Buy 18 Nov 2020
Value US$9,416.00 | Price 11.77 | Shares 800
Buy 18 Nov 2020
Value US$9,416.00 | Price 11.77 | Shares 800
Buy 17 Nov 2020
Value US$9,343.20 | Price 11.68 | Shares 800
Sale 13 Nov 2020
Value US$127,290.00 | Price 12.73 | Shares 10,000
Buy 4 Nov 2020
Value US$22,670.00 | Price 11.34 | Shares 2,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-18 2026-05-14 B Purchase
3.3
KERSTEN GEERT R

Chief Executive Officer

Executive Director
75,825 -27.8%
246.80
US$3,842,495 		75,825 -27.8% 246.80 US$3,842,495
2026-05-14 2026-05-13 B Purchase
3.3
KERSTEN GEERT R

Chief Executive Officer

Executive Director
99,793 -1.2%
494.55
US$4,350,766 		99,793 -1.2% 494.55 US$4,350,766
2026-01-26 2026-01-22 B Purchase
3.3
KERSTEN GEERT R

Chief Executive Officer

Executive Director
1,870 -22.3%
431.38
US$4,022,268 		1,870 -22.3% 431.38 US$4,022,268
2025-12-05 2025-12-04 B Purchase
3.3
KERSTEN GEERT R

Chief Executive Officer

Executive Director
8,389 +11.4%
5.96
US$49,998 		8,389 +11.4% 5.96 US$49,998
2025-07-29 2025-07-25 B Purchase
2.9
Watson Robert Eugene
Non-Executive Director
2,919 +358.6%
6.85
US$19,995 		2,919 +358.6% 6.85 US$19,995
2025-07-28 2025-07-25 B Purchase
3.3
KERSTEN GEERT R

Chief Executive Officer

Executive Director
29,197 +66.9%
6.85
US$199,999 		29,197 +66.9% 6.85 US$199,999
2024-05-10 2024-05-08 B Purchase
2.9
Watson Robert Eugene
Non-Executive Director
20,000 +451.4%
1.39
US$27,800 		20,000 +451.4% 1.39 US$27,800
2024-05-10 2024-05-08 B Purchase
2.9
Watson Robert Eugene
Non-Executive Director
20,000 +451.4%
1.39
US$27,800 		20,000 +451.4% 1.39 US$27,800
2024-05-09 2024-05-08 B Purchase
3.2
PRICHEP PATRICIA B

Senior Vice President

Officer
8,000 +3.6%
1.39
US$11,120 		8,000 +3.6% 1.39 US$11,120
2024-05-09 2024-05-08 B Purchase
3.3
KERSTEN GEERT R

Chief Executive Officer

Executive Director
30,000 +2.6%
1.39
US$41,700 		30,000 +2.6% 1.39 US$41,700
2021-10-21 2021-10-19 S Sale
2.2
TALOR EYAL

Chief Scientific Officer

Officer
15,000 -12.5%
11.25
US$168,750 		15,000 -12.5% 11.25 US$168,750
2021-07-07 2021-07-06 B Purchase
4.0
BAILLAVOINE BRUNO JEAN-MARIE
Non-Executive Director
1,250 +26.5%
8.00
US$10,000 		1,250 +26.5% 8.00 US$10,000
2021-06-29 2021-06-28 B Purchase
3.7
YOUNG PETER R
Non-Executive Director
3,000 +11.6%
12.66
US$37,971 		3,000 +11.6% 12.66 US$37,971
2021-04-23 2021-04-22 S Sale
2.1
CIPRIANO JOHN

Senior Vice President

Officer
10,000 -13.7%
24.38
US$243,793 		10,000 -13.7% 24.38 US$243,793
2020-12-16 2020-12-11 B Purchase
3.7
YOUNG PETER R
Non-Executive Director
100 +0.4%
14.24
US$1,424 		100 +0.4% 14.24 US$1,424
2020-11-18 2020-11-18 B Purchase
2.9
Watson Robert Eugene
Non-Executive Director
800 +33.6%
11.77
US$9,416 		800 +33.6% 11.77 US$9,416
2020-11-18 2020-11-18 B Purchase
4.0
BAILLAVOINE BRUNO JEAN-MARIE
Non-Executive Director
800 +20.4%
11.77
US$9,416 		800 +20.4% 11.77 US$9,416
2020-11-18 2020-11-17 B Purchase
3.7
YOUNG PETER R
Non-Executive Director
800 +3.2%
11.68
US$9,343 		800 +3.2% 11.68 US$9,343
2020-11-16 2020-11-13 S Sale
2.1
CIPRIANO JOHN

Senior Vice President

Officer
10,000 -12.0%
12.73
US$127,290 		10,000 -12.0% 12.73 US$127,290
2020-11-06 2020-11-04 B Purchase
3.7
YOUNG PETER R
Non-Executive Director
2,000 +8.7%
11.34
US$22,670 		2,000 +8.7% 11.34 US$22,670
Explore more

More insider trading research around CEL-SCI Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America